Abcam wins two CiteAb awards
- Awards are for antibody company of the year and most exciting antibody validation initiative
Making sure that scientists have the best possible reagents for their research has been one of our core values since Abcam’s earliest beginnings. By providing researchers with reagents that work first time, we are helping to speed up the progress of scientific discovery. That’s why we’re very happy to announce our recent awards from the 2017 CiteAb Antibody Awards.
CiteAb antibody company of the year:Abcam
This award recognises the most successful antibody company based on CiteAb data.
Dr Chalmers, CiteAb said: “This award is made on CiteAb data or the highest total number of citations per antibody (primary and secondary) for the period between January 2016 and December 2016. To step up and claim the number one position here demonstrates that some really hard work done by the Abcam team over recent years is now paying dividends. We congratulate Abcam on their excellent win!”
Most exciting antibody validation initiative:Abcam
This award recognises the best initiatives in antibody validation.
We started our knockout (KO) validation initiative in 2015 and we’ve now validated the specificity of several hundred antibodies using CRISPR-Cas9 technology. This ongoing program is being conducted at an unprecedented scale and is central to our commitment to improving the standards of antibody validation.
Dr Chalmers, CiteAb, said: “We’ve been very involved in the antibody validation movement over the past two years, and saw a number of excellent initiatives discussed at the 2nd International Antibody Validation event we co-hosted in September. We were thrilled to see an excellent standard of entry in this extremely important category, and congratulate Abcam on their deserved win.”
Find out more about our knockout validated antibodies at https://https://www.abcam.com/primary-antibodies/knockout-validation
